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Aims To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of develop-
ing heart failure.
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Methods
and results
Randomized, open-label, blinded-endpoint trial comparing spironolactone (50 mg/day) or control for up to 9
months in people with, or at high risk of, coronary disease and raised plasma B-type natriuretic peptides. The
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primary endpoint was the interaction between baseline serum galectin-3 and changes in serum procollagen type-III
N-terminal pro-peptide (PIIINP) in participants assigned to spironolactone or control. Procollagen type-I C-terminal
pro-peptide (PICP) and collagen type-1 C-terminal telopeptide (CITP), reflecting synthesis and degradation of type-
I collagen, were also measured. In 527 participants (median age 73 years, 26% women), changes in PIIINP were simi-
lar for spironolactone and control [mean difference (mdiff): -0.15; 95% confidence interval (CI) -0.44 to 0.15 lg/L;
P = 0.32] but those receiving spironolactone had greater reductions in PICP (mdiff: -8.1; 95% CI -11.9 to -4.3 lg/L;
P < 0.0001) and PICP/CITP ratio (mdiff: -2.9; 95% CI -4.3 to -1.5; <0.0001). No interactions with serum galectin
were observed. Systolic blood pressure (mdiff: -10; 95% CI -13 to -7 mmHg; P < 0.0001), left atrial volume (mdiff:
-1; 95% CI -2 to 0 mL/m2; P = 0.010), and NT-proBNP (mdiff: -57; 95% CI -81 to -33 ng/L; P < 0.0001) were reduced
in those assigned spironolactone.
...................................................................................................................................................................................................
Conclusions Galectin-3 did not identify greater reductions in serum concentrations of collagen biomarkers in response to spir-
onolactone. However, spironolactone may influence type-I collagen metabolism. Whether spironolactone can delay
or prevent progression to symptomatic heart failure should be investigated.
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Introduction
Many people with cardiovascular disease will develop heart failure,
leading to substantial disability, demands on health-services and mor-
tality.1,2 Early identification of cardiac dysfunction and therapeutic tar-
geting of specific pathways of disease progression, such as myocardial
and vascular fibrosis,3–12 might delay or prevent the onset of heart
failure.
Mineralo-corticoid receptor antagonists (MRA) improve cardiac
structure, function and prognosis in patients with a reduced left ven-
tricular ejection fraction (LVEF) and heart failure (HFrEF), and per-
haps also when LVEF is preserved (HFpEF).13–15MRA also reduce
serum markers of collagen synthesis in patients with a range of
cardiovascular diseases, including HFrEF and HFpEF,9,11 which might
reflect favourable effects on fibrosis. Galectin-3 is a proposed marker
of fibrotic activity16,17 and, in experimental models, a mediator of
aldosterone-induced fibrosis.18 In the general population, higher
plasma concentrations of galectin-3 predict the development of heart
failure and, subsequently, a worse outcome.19,20
Accordingly, we investigated whether spironolactone had favour-
able effects on serum markers of collagen metabolism in people at
increased risk of developing heart failure and whether the effect was
greater in patients with higher serum concentrations of galectin-3.
Methods
Trial design and oversight
Heart ‘OMics’ in AGEing (HOMAGE) is a research consortium, based in
Europe, investigating biomarkers for predicting incident heart failure in
older people and bio-targets for interventions that might prevent it;
assets include several large clinical databases and collections of biological
material.21,22 The HOMAGE clinical trial was a prospective, randomized,
open-label, blinded-endpoint (PROBE) multi-centre trial, investigating the
effects of MRA on markers of collagen metabolism and cardiovascular
structure and function in people at increased risk of developing heart fail-
ure.11 The protocol and statistical analysis plan are available at https://clini
caltrials.gov/ct2/show/NCT02556450. The trial was funded by the
European Union 7th Framework Programme for Research and
Technological Development (grant: 305507 http://www.homage-hf.eu).
The sponsor was ACS Biomarkers (Amsterdam, The Netherlands). The
European Drug Development Hub (EDDH) (Nancy, France) managed
monitoring and data collection. The trial was approved by relevant ethics
committees and regulatory bodies. Participants provided written,
informed consent. An executive committee developed the protocol,
oversaw trial conduct, and interpreted the results. A clinical endpoints
committee adjudicated hospitalizations and deaths blind to assigned treat-
ment. An independent data monitoring committee oversaw safety.
Trial population
People of either sex, aged >_65 years (amended to >_60 years) at increased
risk of developing heart failure because they had, or were at high risk of,
coronary disease were screened at hospital clinical research clinics.
Those with a plasma amino-terminal pro-B-type natriuretic peptide (NT-
proBNP) of 125–1000 ng/L or BNP 35–280 ng/L were eligible for ran-
domization provided none of the exclusion criteria were met. This ‘win-
dow’ excluded people at low risk of developing heart failure and those
with advanced disease requiring further investigation and treatment. The
main exclusion criteria (Supplementary material online, Table S1) were an
estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2,23 serum
potassium >5.0 mmol/L, LVEF <45%, atrial fibrillation, a diagnosis of heart
failure, or treatment with loop diuretics. Background therapy could in-
clude any conventional treatment except loop diuretics, MRA, or other
potassium-sparing diuretics. Other treatments for concomitant condi-
tions, such as hypertension, diabetes mellitus, or coronary disease, were
permitted.
Aims and endpoints
Serum concentration of procollagen type-III N-terminal pro-peptide
(PIIINP), thought to reflect type-III collagen synthesis, was chosen as the
marker of response, based on a landmark trial of spironolactone for
HFrEF.9 Serum galectin-3 was chosen as a marker of fibrotic activity.16,17
The primary endpoint was the interaction between changes in PIIINP
from baseline to final visit and baseline galectin-3.
Secondary aims were to investigate the effects of spironolactone on
other serum markers of collagen metabolism, on cardiac structure and
function (assessed by echocardiography and NT-proBNP), and on exer-
cise capacity. Specific secondary endpoints included changes in serum
markers of type-I collagen synthesis (procollagen type-I C-terminal pro-
peptide; PICP) and degradation (collagen type-1 C-terminal telopeptide;
CITP), galectin-3 and NT-proBNP; echocardiographic left atrial volume
and left ventricular mass; Doppler measures of cardiac function; tricuspid
2 J.G.F. Cleland et al.
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annular plane systolic excursion (TAPSE) and an incremental shuttle
walk-test.24 Safety endpoints included incidences of serum potassium
>5.5 or <3.5 mmol/L, decline in eGFR by >20%, and a clinical composite
of heart failure or atrial fibrillation, non-fatal myocardial infarction or
stroke or cardiovascular death.11
Laboratory assays
Blind to clinical data and randomization, PIIINP and CITP were measured
by radio-immunoassay (Orion DiagnosticaVR ), PICP by enzyme immune-
assay (METRA; Quidel CorporationVR ) and matrix metalloproteinase-1
(MMP-1) by an amplified luminescent proximity homogenous assay
(ALPHA-LISA) (PerkinElmerVR ). Galectin-3 was measured by enzyme-
linked immunosorbent assay (ELISA) (BG MedicineVR ) and NT-proBNP,
high-sensitivity troponin T (hsTnT) and growth differentiation factor 15
(GDF-15) by electro-chemi-luminescence (ELECSYSVR 2010 analyser;
Roche Diagnostics, Mannheim, Germany). All intra-assay variations were
<10%.
Echocardiography
Echocardiograms were recorded, de-identified and transferred to a core
laboratory (University Hospital of Nancy). Blind to treatment allocation,
a single experienced echocardiographer (Erwan Bozec) measured varia-
bles using dedicated software (Echo PAC, GE Healthcare).
Measurements were repeated at least 2 months later, blind to the first
measurement. All recordings with suboptimal images and/or with differ-
ences >10% were reviewed by a senior cardiologist (Nicolas Girerd) to
exclude measurement error.
Randomization and blinding
Participants were randomized by a co-ordinating centre (Leuven) using
statistical software (SAS 9.4), web-based management system and ran-
dom, permuted blocks, stratified by site. Spironolactone was initiated at
25 mg/day. Doses could be increased up to 50 mg/day or reduced to
25 mg every other day or stopped with or without re-initiation according
to serum potassium and renal function (Supplementary material online,
Table S2). Those assigned to the control group received no additional
treatment. All core-laboratory staff and the clinical endpoints committee
were blind to treatment allocation, but investigators were not.
Follow-up
After randomization, follow-up visits were planned after 1 week and at 1,
2, 3, 6, and 9 months, to assess serum potassium, renal function, and
blood pressure. At the 1-month and final visits, baseline assessments
were repeated, although echocardiography was not mandated at 1
month. The final visit was planned to occur at 9 months. Due to slow re-
cruitment, enrolment was extended but due to the fixed funding-
duration, the final visit occurred between 3 and 8 months for some
participants.
Statistical analysis
Sample-size was based on a test for interaction by analysis of variance25
and required 800 participants to detect an interaction term of 0.79lg/L
between PIIINP and median galectin-3 with a two-sided significance of 5%
and 90% power, given a residual standard deviation for PIIINP of 1.73lg/
L.26 Analyses (StataVR version 15.1) used the intention-to-treat principle.
Baseline characteristics were summarized for categorical variables using
frequencies and percentages, and for continuous variables using median
and interquartile range (IQR, defined as the 1st and 3rd quartiles).
Analysis of covariance (ANCOVA) was used for the primary endpoint. A
linear regression model was fitted, including variables to indicate treat-
ment group, galectin-3 above or below median, and baseline PIIINP. An
interaction term was included to evaluate the effect of spironolactone
when galectin-3 was above median. Residual analysis was used to examine
the fit of the model to the assumptions of linear regression with data
transformed as required. Secondary endpoints were analysed using
ANCOVA for continuous data or multi-variable logistic regression for
composite clinical events. No adjustments were made for multiple com-
parisons to allow for type-1 error in view of the exploratory nature of
this proof-of-concept trial.
Results
Between January 2016 and June 2018, 877 patients were consented,
of whom 561 were eligible and 527 were randomized
(Figure 1—Consort Diagram; Supplementary material online, Table
S3). The main reason for exclusion was NT-proBNP <125 ng/L or
BNP <35 ng/L. Baseline characteristics of those assigned to spirono-
lactone or control were similar (Table 1). Median age was 73 (IQR
68–78) years, 26% were women, 72% had coronary disease, 42% had
diabetes, and 22% had an eGFR <60 mL/min/1.73 m2. Most partici-
pants (78%) had a history of hypertension, were overweight or obese
and, despite receiving two or more anti-hypertensive medications,
50% had a systolic blood pressure >140 mmHg. Participants
reported breathlessness at moderate levels of exertion (Table 1) and
the shuttle walk-test (Table 2) was mildly impaired (50; IQR 32–70
completed shuttles) compared with published normal values (mean
± SD for general population age >_70 years is 63 ± 19 shuttles).24 The
rise in heart rate with exercise was modest (many participants were
receiving beta-blockers) but systolic blood pressure rose from 140
(IQR 127–155) mmHg to 165 (IQR 144–187) mmHg. Left ventricular
volumes, ejection fraction, and mass were normal but left atrial vol-
ume [31 (IQR 26–37) mL/m2], plasma NT-proBNP (median 214; IQR
137–356 ng/L),27 and serum galectin-3 (median 16.1; IQR 13.5–
19.7mg/L) were increased19 (Table 2). Serum concentrations of
markers of collagen metabolism were not greater than published
normal values but this could reflect differences amongst assays11,28
(Table 2). Participants with a serum galectin-3 above median had
higher serum CITP and NT-proBNP but similar PIIINP and PICP.
Follow-up
Data were acquired on 506 (96%) patients at the final visit; 345 (68%)
had >250 days of follow-up (Supplementary material online, Figure
S1). At the 1-month visit, of those assigned to spironolactone, 99
were prescribed 50 mg/day, 118 were prescribed 25 mg/day, 26 were
prescribed 25 mg every other day, 10 were not prescribed spirono-
lactone, and information on dose was missing for 12. No participant
assigned to the control group was prescribed an MRA. During the
trial, serum potassium exceeded 5.5 mmol/L in seven participants
assigned to spironolactone but only one developed a value
>6.0 mmol/L. Two participants in each group died. Fourteen clinical
composite endpoints occurred in 11 participants assigned to placebo
and 12 endpoints in nine participants assigned to spironolactone
(P = 0.50) (Supplementary material online, Table S4).
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fibrosis
Serum PIIINP changed little during follow-up, with a mean difference
between groups from baseline to the final visit of -0.15lg/L (95% CI
-0.44 to 0.15; P = 0.323); there was no interaction (P = 0.947) with
galectin-3 (Figure 2; Table 3). However, in those assigned to spirono-
lactone, there was a greater decline in serum PICP (mean difference
-8.1lg/L; 95% CI -11.9 to -4.3; P < 0.001) and increase in CITP and
consequently, a greater decline in PICP/CITP ratio (mean difference
-2.9; 95% CI -4.3 to -1.5; P < 0.001) but, again, no interaction with
CONSORT Flow Diagram 
Assessed for eligibility (n=877) 
Excluded (n=350) 
• Natriuretic Peptide Out of Range: 253 
• Atrial Fibrillation: 16 
• LVEF <45%: 13 
• Serum K >5.0mmol/L: 9 
• Receiving Loop Diuretic or MRA: 7 
• Valve Disease: 5 
• Other reasons: 48 
Analysed  (n=255) 
♦ Excluded from analysis 
 Death (n=2) 
 Did not attend final visit (n=5) 
Median (IQR) follow-up 267 (184 to 275) days
Lost to follow-up (give reasons) (n=0) 
Discontinued intervention (n=0) 
Allocated to control (n=262) 
♦ Received allocated intervention (n=262)
♦ Did not receive allocated intervention (n=0)
Lost to follow-up (give reasons) (n=0) 
Discontinued intervention (n=10) 
Allocated to intervention (n=265) 
♦ Received allocated intervention (n=255)
♦ Did not receive allocated intervention (n=10)
Analysed  (n=251) 
♦ Excluded from analysis (give reasons)  
Death (n=2) 
Did not attend final visit (n=12)  
Median (IQR) follow-up 266 (176 to 274) days
Allocation 
Analysis 
Follow-Up
Randomized (n=527) 
Enrollment 
Figure 1 Consort diagram showing patient disposition, including screening, randomization, and follow-up.
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..galectin-3 was observed (Figure 2; Table 3). Serum MMP-1 did not
change. Serum galectin-3 increased at both time points for those
assigned to spironolactone (Table 2).
Secondary endpoints
Systolic blood pressure (mean difference -10 mmHg; 95% CI -13 to
-7; P < 0.001) and plasma NT-proBNP (mean difference -41 ng/L;
95% CI -75 to -11; P = 0.009) were lower at the final visit in those
assigned to spironolactone but symptoms, exercise capacity, haemo-
globin, troponin, and GDF-15 were no different (Figure 3; Tables 4
and 5). Serum concentrations of sodium fell, and serum potassium,
urea and creatinine rose on spironolactone. Small reductions in QRS
duration (P = 0.003), left atrial volume index (P = 0.010), left ventricu-
lar mass index (P = 0.079) and early mitral flow (E-wave) velocity
(P < 0.001), and increases in LVEF (P = 0.022) were observed in those
assigned to spironolactone (Table 5) but the ratio of E to early
.......................................................... ..........................................................
....................................................................................................................................................................................................................
Table 1 Patient characteristics at baseline
Control Spironolactone
N 5 262 N 5 265
Demographics and lifestyle Median Quartiles 1 & 3 Median Quartiles 1 & 3
Age (years) 73 (68 to 78) 73 (69 to 79)
N = % N = %
Women 75 (29) 60 (23)
Current smoker 20 (8) 24 (9)
Prior medical history, N (%) N = % N = %
Hypertension 199 (76.0) 214 (80.8)
Diabetes mellitus 109 (41.6) 110 (41.5)
Coronary artery disease 190 (72.5) 190 (71.7)
Myocardial infarction 103 (39.3) 113 (42.6)
Percutaneous coronary intervention 138 (52.7) 129 (48.7)
Coronary artery bypass graft 69 (26.3) 67 (25.3)
Stroke/transient ischaemic attack 13 (5.0) 15 (5.7)
Medications N = % N = %
Thiazide diuretics 41 (15.6) 46 (17.4)
ACE inhibitors 140 (53.4) 135 (50.9)
Angiotensin receptor blockers 71 (27.1) 74 (27.9)
Beta-blockers 180 (68.7) 186 (70.2)
Calcium channel blockers 51 (19.5) 59 (22.3)
Lipid-lowering therapy 217 (82.8) 218 (82.3)
Aspirin 181 (69.1) 195 (73.6)
Any antiplatelet (including aspirin) 205 (78.2) 209 (78.9)
New York Heart Association Class N = % N = %
I 219 (83.6) 223 (84.2)
II 35 (13.4) 33 (12.5)
III 5 (1.9) 5 (1.9)
Patients self-rated symptoms Median Quartiles 1 & 3 Median Quartiles 1 & 3
Breathless on moderate exertion 5 (2 to 6) 5 (2 to 6)
Ankle swelling 0 (0 to 2) 0 (0 to 2)
EQ5D VAS 80 (70 to 90) 76 (66 to 85)
Physical examination Median Quartiles 1 & 3 Median Quartiles 1 & 3
Weight, kg 81.7 (71.0 to 91.0) 82.0 (73.0 to 92.3)
BMI, kg/m2 27.6 (25.3 to 31.4) 28.4 (25.4 to 31.7)
Heart rate, b.p.m. 61 (54 to 67) 60 (55 to 67)
Systolic blood pressure, mmHg 140 (128 to 155) 140 (126 to 155)
Diastolic blood pressure, mmHg 77 (71 to 84) 78 (71 to 85)
Systolic blood pressure category N = % N = %
140–159 mmHg 87 (33.2) 92 (34.7)
>_160 mmHg 45 (17.2) 45 (17.0)
BMI, body mass index; VAS, visual analogue score.
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Table 2 Investigations at baseline
Control Spironolactone
Baseline investigations N 5 262 N 5 265
Shuttle walk-test Median Quartiles 1 & 3 Median Quartiles 1 & 3
Number of shuttles completed 50 (32 to 70) 48 (33 to 65)
Breathlessness score after exercise 5 (3 to 7) 5 (3 to 7)
Post-exercise heart rate, b.p.m. 76 (64 to 93) 76 (64 to 90)
Post-exercise, systolic BP, mmHg 165 (144 to 187) 165 (144 to 188)
Electrocardiogram and echocardiography
QRS duration (ms) 92 (84 to 102) 92 (84 to 108)
LV end-diastolic volume index (mL/m2) 42 (36 to 49) 41 (35 to 48)
LV ejection fraction (%) 63 (57 to 66) 63 (59 to 67)
Left ventricular mass index (g/m2) 95 (81 to 113) 94 (81 to 111)
Men 97 (79 to 103) 94 (82 to 111)
Women 88 (79 to 103) 96 (81 to 109)
Left atrial volume index (mL/m2) 31 (26 to 37) 30 (26 to 35)
Early mitral flow velocity (E) m/s 0.7 (0.6 to 0.8) 0.7 (0.6 to 0.8)
Late (atrial) mitral flow velocity (A) m/s 0.8 (0.7 to 0.9) 0.8 (0.7 to 0.9)
E/A ratio 0.8 (0.7 to 1.0) 0.8 (0.7 to 1.0)
E/ early diastolic tissue velocity (e’) ratio 9.4 (7.5 to 11.8) 9.2 (7.6 to 11.3)
Tricuspid annular plane systolic excursion 22.4 (16.7 to 26.6) 21.7 (17.5 to 26.2)
Blood tests
Haemoglobin, g/dL 14.1 (13.2 to 14.9) 14.0 (13.1 to 14.9)
Sodium, mmol/L 139 (138 to 141) 140 (138 to 141)
Potassium, mmol/L 4.3 (4.1 to 4.6) 4.3 (4.0 to 4.6)
Creatinine, mmol/L 84 (74 to 98) 84 (71 to 100)
Galectin-3, mg/L 16.1 (13.2 to 19.7) 16.0 (13.8 to 19.7)
High-sensitivity troponin-T, ng/L 12.9 (9.2 to 18.5) 12.7 (8.4 to 17.6)
Growth differentiation factor, 15 ng/L 1,421 (1,011 to 1,954) 1,467 (1,076 to 2,207)
Collagen markers and NT-proBNP
PIIINP, mg/L 4.0 (3.0 to 5.2) 3.9 (3.2 to 4.9)
PICP, mg/L 80.9 (67.2 to 97.6) 79.1 (63.2 to 97.0)
CITP, mg/L 3.8 (2.9 to 5.1) 3.7 (2.8 to 4.8)
MMP-1, mg/L 10.2 (6.7 to 15.3) 10.2 (6.7 to 17.1)
PICP/CITP, ratio 20.7 (15.6 to 28.9) 21.7 (16.2 to 28.3)
NT-proBNP, ng/L (core lab) 217 (134 to 334) 206 (135 to 368)
Galectin-3 below median
PIIINP, mg/L 3.8 (3.0 to 5.1) 3.7 (3.1 to 4.6)
PICP, mg/L 79.2 (66.5 to 95.6) 80.4 (65.4 to 94.8)
CITP, mg/L 3.4 (2.7 to 4.2) 3.2 (2.7 to 4.3)
MMP-1, mg/L 10.2 (6.5 to 14.0) 9.1 (6.7 to 15.5)
PICP/CITP ratio 22.0 (17.5 to 30.3) 23.6 (17.3 to 29.8)
NT-proBNP, ng/L (core lab) 195 (119 to 292) 172 (132 to 296)
Galectin-3 above median
PIIINP, mg/L 4.1 (3.1 to 5.3) 4.0 (3.2 to 4.9)
PICP, mg/L 81.2 (69.9 to 98.7) 78.4 (63.1 to 103.2)
CITP, mg/L 4.1 (3.1 to 5.6) 4.1 (3.0 to 5.3)
MMP-1, mg/L 10.2 (6.7 to 15.7) 11.3 (6.7 to 18.8)
PICP/CITP, ratio 19.6 (14.7 to 25.5) 19.6 (14.7 to 26.6)
NT-proBNP, ng/L (core lab) 239 (145 to 374) 263 (140 to 454)
BP, blood pressure; CITP, collagen type-1 C-terminal telopeptide; LV, left ventricular; MMP-I, matrix metalloproteinase-1; NT-proBNP, amino-terminal B-type natriuretic pep-
tide; PICP, procollagen type-I C-terminal pro-peptide; PIIINP, procollagen type-III N-terminal pro-peptide.
6 J.G.F. Cleland et al.
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..diastolic tissue velocity (e0) did not change. At 1 month, results were
generally similar to those observed at the end of the trial.
Discussion
In contrast to some previous reports, we did not show reductions in
serum PIIINP after administration of spironolactone nor did we ob-
serve an interaction with baseline serum galectin-3.11 However, we
did observe a decline in serum PICP and a rise in CITP with
spironolactone, suggesting, respectively, reduced synthesis and
increased degradation of type-I collagen.10,29–31 Changes in PICP and
CITP were prominent within 1 month, persisted and were accompa-
nied by reductions in left atrial volume and increases in LVEF in the
longer term, indicating favourable effects on cardiac structure and
function (Take home figure).
Type-I collagen comprises large-diameter fibres with a high pro-
pensity for cross-linking that make a substantial contribution to myo-
cardial stiffness compared with the finer type-III collagen fibres.10
Pathological myocardial fibrosis is characterized by an excess of
Figure 2 Changes from baseline to 1 month and final visits for serum concentrations of (A) procollagen type-III N-terminal pro-peptide (PIIINP);
(B) procollagen type-III N-terminal pro-peptide for those with a baseline serum galectin above or below median; (C) procollagen type-I C-terminal
pro-peptide (PICP); (D) collagen type-1 C-terminal telopeptide (CITP); (E) the ratio of procollagen type-I C-terminal pro-peptide to collagen type-1
C-terminal telopeptide; (F) Galectin-3. Data shown are mean change and standard deviation. P-values are for the comparison between intervention
and control except for (B) where the P-values refer to the interaction between baseline serum galectin-3 and changes in plasma concentrations of
procollagen type-III N-terminal pro-peptide. The interaction between baseline galectin-3 and change from baseline to final visit in procollagen type-III
N-terminal pro-peptide was the primary endpoint of the trial (P = 0.947 for the interaction).
Spironolactone, fibrosis and cardiovascular function 7
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..type-I compared with type-III collagen that, along with hypertrophy,
contributes to a restrictive ventricular pathophysiology, leading to
increases in diastolic ventricular pressures and atrial dilation that may
culminate in HFpEF.10,11,30,32 Our data suggest that MRA might re-
duce or reverse accumulation of type-I collagen but have little or no
effect on type-III collagen, effects that might be considered advanta-
geous for an intervention aimed at preventing or reversing patho-
logical myocardial fibrosis. If changes in serum markers of type-1
collagen also indicate a favourable clinical response to spironolac-
tone, this casts doubt on the utility of galectin-3 as a means of select-
ing patients for treatment with spironolactone, if future trials show
that MRA can delay or prevent the onset of heart failure.
We are aware of only one study that obtained myocardial biopsies
before and after administration of spironolactone in patients with
heart failure,33 where a serum PICP/CITP of >35, rare amongst par-
ticipants in our trial, had more myocardial fibrosis and a greater abun-
dance of both type-I and type-III collagen. Spironolactone reduced
both PICP/CITP ratio and myocardial collagen fraction. Several other
trials have investigated the effects of spironolactone on serum colla-
gen markers in a broad range of cardiovascular diseases,11 generally
showing that serum PIIINP was not markedly different in people with
and without cardiovascular disease but that administration of MRA to
patients with severe HFrEF reduced serum PIIINP, which is why it
was chosen as the primary efficacy marker for HOMAGE.11
Figure 3 Changes from baseline to 1 month and to the final visit in (A) systolic blood pressure; (B) plasma concentrations of NT-proBNP; (C) left
atrial volume index; (D) E/A ratio; (E) serum potassium; (F) estimated glomerular filtration rate. Data shown are mean change and standard deviation.
P-values are for the comparison between intervention and control.
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..However, in one substantial trial of patients with less severe HFrEF,
canrenone, the active metabolite of spironolactone, did not reduce
serum PIIINP, despite reducing left ventricular mass, left atrial diam-
eter, and B-type natriuretic peptide and increasing LVEF.34
Differences between assays or disease-state may account for these
apparent inconsistencies.
Serum PICP is raised in people with cardiovascular disease and
also declines with administration of an MRA.11,35 Fewer trials have
investigated the effects of MRA on serum CITP and found no consist-
ent effect.11 Duration of treatment may be important; we observed
clearer reductions in CITP with spironolactone at 1 month compared
with the final visit, which might reflect an early increase in the rate of
collagen turnover before it subsides to a new steady-state. We
observed a rise in galectin-3 with the administration of spironolac-
tone as have others.36 This might reflect increased galectin-3 produc-
tion due to potassium-mediated increases in aldosterone subsequent
to administration of an MRA,37 or reduced galectin-3 clearance due
to the decline in eGFR.
Spironolactone reduced collagen marker within a few weeks, sug-
gesting that they reflect changes in the rate of turnover rather than
the mass of collagen. However, a favourable effect on turnover
should eventually reduce fibrosis. Blood concentrations of bio-
markers reflect the equilibrium between production and disposal.
Plasma concentrations of biomarkers cleared by the kidney should
rise because eGFR declines with the introduction of MRA. This sug-
gests that the decline in PICP is due to reduced production, which
could reflect favourable effects of MRA on ventricular pre- and after-
load or a direct effect of spironolactone on collagen production or
processing.29,38 Many of our participants had inadequately controlled
blood pressure, which fell substantially in those assigned to spirono-
lactone, as observed in trials of resistant hypertension,39 and was
accompanied by a decline in NT-proBNP and, in the longer term,
echocardiographic evidence of cardiac remodelling. However, the
heart contains only a small proportion of the body’s collagen. If spir-
onolactone has a specific effect only on cardiovascular collagen, then
the effect would have to be very large in order to change serum
Take home figure: Diagram showing the evolution from risk factors, through structural heart disease to heart failure and the randomized con-
trolled trials of mineralo-corticoid receptor antagonists (MRA) that have addressed each stage. The PATHWAY-2 trial39 demonstrated the effects of
spironolactone on blood pressure, a key risk factor for heart failure. HOMAGE is the only trial, to date, that has focused on patients with structural
heart disease with few or no symptoms of heart failure. The ALDO-DHF trial14 showed favourable effects on ventricular filling in patients with a pre-
served left ventricular ejection fraction (LVEF) and heart failure (HFpEF). Many patients in ALDO-DHF had less severe cardiac dysfunction than in
HOMAGE; there is substantial overlap in the patient characteristics of these two trials. TOPCAT15 investigated the effects of spironolactone in
HFpEF with equivocal results. EMPHASIS,13 AREA IN-CHF,34 and RALES9 investigated the effects of mineralo-corticoid receptor antagonists in
HFrEF (heart failure with a reduced left ventricular ejection fraction). In HOMAGE, spironolactone caused an early reduction in weight, blood pres-
sure, and natriuretic peptides, suggesting a natriuretic and diuretic effect. Changes in serum markers of type-1, although not type-III, collagen metabol-
ism were also observed within 1 month. This combination of effects was followed by favourable cardiac remodelling. Type-1 collagen is the more
important contributor to myocardial stiffness. The magnitude of changes in collagen metabolites observed suggests a systemic effect of spironolac-
tone rather than only on the myocardium.
12 J.G.F. Cleland et al.
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..marker concentrations. It is more likely that changes in serum PICP
indicate an effect on fibroblasts in many organs.10
Assuming an extra-cellular fluid volume of 15 L, a rise in serum po-
tassium concentration of just 0.2 mmol/L, as we observed, would re-
quire retention of only 3–4 mmol of potassium. If MRA cause
retention of much larger amounts, as is likely,40 potassium must be
transferred to the intra-cellular space and, therefore, assuming no
change in intra-cellular potassium concentration, intra-cellular water
must increase.41 Accordingly, changes in weight may underestimate
the effect of spironolactone on extra-cellular water volume. NT-
proBNP and left atrial volume both declined on spironolactone,
implying a reduction in cardiac filling pressures that might be due to a
subtle reduction in plasma volume, although haemoglobin did not
change, or a reduction in afterload or improved myocardial function.
Serum sodium concentration fell, implying even greater loss of extra-
cellular sodium than of water.
Our population had normal left ventricular end-diastolic volumes
and LVEF but left atrial volume and left ventricular mass were
increased. We excluded patients with a diagnosis of heart failure or
atrial fibrillation and those taking loop diuretics but, with the excep-
tion of E/e0, our patients had more severe cardiac dysfunction than
many of those enrolled in trials of HFpEF.11 Many of our patients also
reported breathlessness on moderate exertion and had reduced ex-
ercise capacity and therefore fulfilled all of the diagnostic criteria for
HFpEF; symptoms, reduced exercise capacity, cardiac dysfunction
and raised NT-proBNP. Spironolactone reduced left atrial volume
and NT-proBNP, suggesting favourable effects on cardiac structure
and function that could delay or prevent the onset of clinically overt
heart failure, although our trial was neither large nor long enough to
demonstrate such an effect and no differences in symptoms or exer-
cise capacity were observed.
The HOMAGE trial did not enrol the pre-specified number of par-
ticipants or follow all those included for the intended duration.
However, even if we had conducted the trial as originally planned a
different result is unlikely. Interpretation of secondary endpoints in a
clinical trial with a neutral primary endpoint should be considered hy-
pothesis-generating rather than definitive. Also, we did not make
adjustments for multiple hypothesis testing. Many patients had poorly
controlled hypertension and, as discussed above, reduction in blood
pressure could have made an important contribution to our results.
We cannot exclude the possibility that some of our patients had
transthyretin or other types of cardiac amyloidosis. Our trial was a
mechanistic proof-of-concept trial and should be interpreted in the
context of information from other trials.
In conclusion, spironolactone did not reduce serum concentra-
tions PIIINP and serum galectin-3, measured at baseline, did not iden-
tify a subgroup with a greater response. The effect of spironolactone
on PICP/CITP ratio appears early and is sustained, suggesting that the
effects of MRA on type-I collagen metabolism may be underappreci-
ated. Future research on the effects of MRA and other interventions
on collagen metabolism in cardiac disease should consider measuring
PICP/CITP as evidence of biological activity. The effects of spironolac-
tone on type-I collagen turnover, blood pressure and cardiac function
in people with a cardiovascular profile consistent with clinically occult
HFpEF, indicate the need for clinical trials to determine whether
timely intervention with an MRA can delay or prevent progression to
clinically overt heart failure.
Supplementary material
Supplementary material is available at European Heart Journal online.
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